论文部分内容阅读
目的探讨注射用重组人干扰素α1b压缩雾化治疗毛细支气管炎的临床疗效。方法将郑州市一院2009年6月—2011年6月收治的毛细支气管炎228例患儿随机分为2组,治疗组及对照组各114例,在常规治疗的基础上治疗组加用注射用重组人干扰素α1b压缩雾化吸入,2万U/kg·d,每日2次,每次5~10min,疗程5d,对照组,利巴韦林注射液10 mg/kg·d,分2次雾化吸入,每次5~10min,疗程5d。结果治疗组总有效率及对照组总有效率分别为92.12%、72.86%,差异有统计学意义(P<0.05);治疗组和对照组在喘憋、咳嗽、喘鸣音消失时间及住院天数分别为(1.95±1.45,3.38±1.35,4.38±1.35,5.76±1.22)(2.75±1.58,5.25±1.57,5.38±1.35,7.98±1.61),均优于对照组,差异有统计学意义(P<0.05),无不良反应发生。结论应用注射用重组人干扰素α1b压缩雾化吸入治疗婴幼儿毛细支气管炎安全,有效。
Objective To investigate the clinical efficacy of injection of recombinant human interferon α1b compression atomization for the treatment of bronchiolitis. Methods A total of 228 children with bronchiolitis admitted from June 2009 to June 2011 in Zhengzhou City were randomly divided into two groups. The treatment group and the control group included 114 cases each. On the basis of routine treatment, With inhaled interferon α1b recombinant inhalation, 20,000 U / kg · d, 2 times a day, each 5 ~ 10min, treatment 5d, the control group, ribavirin injection 10 mg / kg · d, points 2 times inhalation, each 5 ~ 10min, course of treatment 5d. Results The total effective rate of the treatment group and the control group were 92.12% and 72.86%, respectively, with significant difference (P <0.05). The treatment group and the control group had no significant differences in wheezing, cough, wheezing disappearance time and hospital stay (1.95 ± 1.45,3.38 ± 1.35,4.38 ± 1.35,5.76 ± 1.22) (2.75 ± 1.58,5.25 ± 1.57,5.38 ± 1.35,7.98 ± 1.61, respectively), which were all better than the control group, the difference was statistically significant (P <0.05), no adverse reactions occurred. Conclusions It is safe and effective to treat infantile bronchiolitis by injecting atomized inhalation with recombinant human interferon α1b.